This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of
STK-012 as monotherapy and in combination with pembrolizumab in patients with selected
advanced solid tumors.

The phase 1a portion of the study is standard 3+3 dose escalation design to evaluate STK-012
as monotherapy and in combination with pembrolizumab in patients with selected solid tumors
who have progressed after standard of care treatments. The phase 1b portion of the study
includes dose expansions to evaluate STK-012 as monotherapy and in combination with
pembrolizumab at the candidate recommended phase 2 dose (RP2D) in selected solid tumor types.

Selected Inclusion Criteria

1. Patients must have selected tumor types and must have progressed after standard of
care treatment, or be intolerant to treatment, or refused standard treatment.

2. Patients must be amenable to a fresh tissue biopsy, unless medically contraindicated.

3. Patients with central nervous system (CNS) metastases must have been treated and be
asymptomatic.

Selected Exclusion Criteria:

1. Received systemic anti-cancer therapy within 3 weeks of the first dose of study
treatment or small molecule kinase inhibitors within 6 elimination half-lives of the
first dose of study treatment.

2. Received radiotherapy within 2 weeks of the first dose of study treatment.

3. Received prior IL-2-based or IL-15-based cytokine therapy.

If you are interested in participating in this study, call The JamesLine at 800-293-5066 to make an appointment with the principal investigator listed or ask your doctor if you are eligible for this study.